Acrux Secures AUD 5.4 Million Milestone Deal for Lenzetto to Address Australian Menopause Therapy Shortage

Milestone Deal Unlocks Australian Launch for Lenzetto®

Acrux Limited (ASX:ACR) has struck an amended licensing agreement with Gedeon Richter Plc that could deliver up to AUD 5.4 million in milestone payments over two years tied to the Australian market launch of Lenzetto®, its transdermal Estradiol spray. The deal includes upfront, regulatory, and commercial milestones, though the exact terms remain commercial-in-confidence.

This development comes as Australia faces a critical shortage of Menopause Hormone Therapy (MHT) options, with Lenzetto® poised to fill that gap. The product’s entry promises Australian women a precise, consistent, and easy-to-use treatment for symptoms linked to oestrogen deficiency after menopause, such as hot flushes.

Leveraging Patchless Patch™ Technology and Global Footprint

Originally developed by Acrux, Lenzetto® utilises the company’s innovative Patchless Patch™ delivery system, a technology invented at Monash University that enables effective transdermal hormone delivery without traditional patches. This technology has already improved treatment accessibility for women globally.

Gedeon Richter markets Lenzetto® in over 40 countries, generating EUR 50 million in sales in 2025, underscoring the product’s established commercial viability. The amended agreement extends this reach to Australia, a market where Acrux has long sought to introduce the product.

John Warmbrunn, Acrux CEO, emphasised the strategic importance of the deal, highlighting both patient access and financial benefits. The milestone payments will bolster Acrux’s position as it advances its pipeline, including its innovative Female Testosterone product. This follows recent capital raising efforts to support clinical trials and co-development partnerships in hormone therapies, reflecting the company’s broader pivot towards female health solutions.

Strategic Implications for Acrux’s Hormone Therapy Pipeline

Beyond the immediate revenue potential, the deal signals Acrux’s commitment to expanding its footprint in the hormone therapy space. The Australian launch of Lenzetto® complements its ongoing work in female testosterone therapies, which recently attracted $1.6 million in funding to back Phase III trials and co-development deals.

Felicia Colagrande, Acrux’s Product Development Director, noted the significance of providing Australian women with a discrete and reliable MHT option, reinforcing the company’s patient-centric approach.

With the amended licensing agreement now in place, Acrux is positioned to capitalise on both unmet clinical needs and financial milestones, while continuing to innovate in women’s health. This milestone deal arrives amid a broader strategy to grow hormone therapy offerings, building on recent advances and funding successes.